Supplementary Table S2 from Phase II Study to Determine the Antitumor Activity and Safety of Simlukafusp Alfa (FAP-IL2v) Combined with Atezolizumab in Esophageal Cancer
Year: 2024
Type: supplementary-materials
Abstract: Duration of most common AEs (reported in ≥20% of patients)
Authors: Hans Prenen, Sanjeev Deva, Bhumsuk Keam, Colin R. Lindsay, Iwona Lugowska, James C. Yang, Federico Longo, Maria de Miguel, Mariano Ponz-Sarvise, Myung-Ju Ahn, Mahmut Gumus, Stephane Champiat, Antoine Italiano, Sébastien Salas, Ruth Perets, Cagatay Arslan, Byoung C. Cho, Stefan Evers, Christophe Boetsch, Daniel Marbach, David Dejardin, Nassim Sleiman, Caroline Ardeshir, Muriel Richard, Jehad Charo, Anton Kraxner, Nino Keshelava, Volker Teichgräber, Victor Moreno
Language: English
Subfield: Surgery
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4400661857